Literature DB >> 28971528

M2 polarization of monocytes in ankylosing spondylitis and relationship with inflammation and structural damage.

Jinzhu Zhao1, Wei Yuan2, Chunsheng Tao1, Peifeng Sun1, Zaixing Yang3, Weidong Xu4.   

Abstract

The aim of this study was to evaluate the polarization of peripheral blood monocytes in the patients with ankylosing spondylitis (AS) and to determine the correlations between monocyte polarization and inflammation and structural damage. A total of 120 AS patients, 50 rheumatoid arthritis (RA) patients and 100 healthy controls were enrolled in the study. M1 (CD68+CD192+) and M2 (CX3CR1+CD163+) monocytes were characterized by flow cytometry. Demographic, clinical, radiographic and laboratory data were collected and analyzed. A large increase in M2 (CX3CR1+CD163+) monocytes was observed in AS, and M2/M1 ratio was 7.18 ± 6.12, 2.54 ± 3.14 and 35.61 ± 20.04 in control, RA and AS, respectively. The M2/M1 ratio correlated with modified Stoke Ankylosing Spondylitis Spine Score (mSASSS) (r = 0.565; p < 0.001), ESR (r = -0.321; p < 0.001, CRP (r = -0.265; p < 0.001) and Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) (r = -0.201; p = 0.028). Anti-TNF-α therapy induced a significant reduction in the percentage of M1 monocyte, ESR, CRP and BASDAI in AS patients. The present results demonstrated that M2 type polarized monocytes are predominant in the peripheral blood in AS and the M2/M1 ratio is correlated with structural damage (mSASSS), inflammatory biomarkers (ESR and CRP) and BASDAI.
© 2017 APMIS. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  Ankylosing spondylitis; disease activity; monocyte polarization; structural damage

Mesh:

Substances:

Year:  2017        PMID: 28971528     DOI: 10.1111/apm.12757

Source DB:  PubMed          Journal:  APMIS        ISSN: 0903-4641            Impact factor:   3.205


  7 in total

1.  Evidence for M2 macrophage activation in patients with enthesitis-related arthritis category of juvenile idiopathic arthritis.

Authors:  Shruti Bhattacharya; Akhilesh Yadav; Amita Aggarwal
Journal:  Clin Rheumatol       Date:  2019-02-08       Impact factor: 2.980

2.  The Diagnostic Significance of CXCL13 in M2 Tumor Immune Microenvironment of Human Astrocytoma.

Authors:  Shu-Jyuan Chang; Chia-Te Chao; Aij-Lie Kwan; Chee-Yin Chai
Journal:  Pathol Oncol Res       Date:  2022-04-28       Impact factor: 2.874

Review 3.  Role of Stem Cells in Pathophysiology and Therapy of Spondyloarthropathies-New Therapeutic Possibilities?

Authors:  Magdalena Krajewska-Włodarczyk; Agnieszka Owczarczyk-Saczonek; Waldemar Placek; Adam Osowski; Piotr Engelgardt; Joanna Wojtkiewicz
Journal:  Int J Mol Sci       Date:  2017-12-28       Impact factor: 5.923

Review 4.  Anti-TNF Therapy in Spondyloarthritis and Related Diseases, Impact on the Immune System and Prediction of Treatment Responses.

Authors:  Silvia Menegatti; Elisabetta Bianchi; Lars Rogge
Journal:  Front Immunol       Date:  2019-03-19       Impact factor: 7.561

5.  Deregulation of microRNA expression in monocytes and CD4+ T lymphocytes from patients with axial spondyloarthritis.

Authors:  Olivier Fogel; Andreas Bugge Tinggaard; Maud Fagny; Nelly Sigrist; Elodie Roche; Laurence Leclere; Jean-François Deleuze; Frederic Batteux; Maxime Dougados; Corinne Miceli-Richard; Jörg Tost
Journal:  Arthritis Res Ther       Date:  2019-02-12       Impact factor: 5.156

Review 6.  Monocytes and Macrophages in Spondyloarthritis: Functional Roles and Effects of Current Therapies.

Authors:  Sara Martínez-Ramos; Carlos Rafael-Vidal; José M Pego-Reigosa; Samuel García
Journal:  Cells       Date:  2022-02-02       Impact factor: 6.600

7.  Serum granulocyte-macrophage colony-stimulating factor (GM-CSF) is increased in patients with active radiographic axial spondyloarthritis and persists despite anti-TNF treatment.

Authors:  Charalampos Papagoras; Styliani Tsiami; Akrivi Chrysanthopoulou; Ioannis Mitroulis; Xenofon Baraliakos
Journal:  Arthritis Res Ther       Date:  2022-08-16       Impact factor: 5.606

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.